PE20171136A1 - Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural - Google Patents
Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma naturalInfo
- Publication number
- PE20171136A1 PE20171136A1 PE2017000941A PE2017000941A PE20171136A1 PE 20171136 A1 PE20171136 A1 PE 20171136A1 PE 2017000941 A PE2017000941 A PE 2017000941A PE 2017000941 A PE2017000941 A PE 2017000941A PE 20171136 A1 PE20171136 A1 PE 20171136A1
- Authority
- PE
- Peru
- Prior art keywords
- mhc
- peptide ligand
- peptide
- absolute quantification
- hla
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Se refiere a un metodo para la cuantificacion absoluta de un ligando peptidico del complejo mayor de histocompatibilidad (MHC) radicado sobre una celula, que comprende: a) preparacion de celulas que presentan el ligando peptidico de MHC a partir de una muestra biologica; b) determinacion del numero de celulas en la preparacion resultante de la etapa a); c) adicionar una cantidad conocida del ligando peptidico-MHC y/o complejo de ligando peptidico-MHC de la etapa a) que se pretende cuantificar (1er enriquecimiento); d) aislar un ligando peptidico del MHC resultante de la preparacion de la etapa c) con el fin de obtener un eluato del peptido; e) adicionar una cantidad conocida del ligando peptidico del MHC que se pretende cuantificar al citado eluato (2do enriquecimiento); f) ejecutar un analisis por espectrometria de masas con un ligando peptidico de MHC; y g) cuantificacion del citado ligando peptidico del MHC basada en la comparacion de las las senales obtenidas en la etapa f). Dicho metodo es util en la inmunovigilancia definida con criterios moleculares y en los procesos de identificacion de nuevos antigenos peptidicos para estrategias inmunoterapeuticas
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462097994P | 2014-12-30 | 2014-12-30 | |
GBGB1423361.3A GB201423361D0 (en) | 2014-12-30 | 2014-12-30 | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20171136A1 true PE20171136A1 (es) | 2017-08-09 |
Family
ID=52471641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017000941A PE20171136A1 (es) | 2014-12-30 | 2015-12-15 | Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural |
Country Status (35)
Country | Link |
---|---|
US (2) | US10545154B2 (es) |
EP (1) | EP3241026B1 (es) |
JP (1) | JP6735741B2 (es) |
KR (1) | KR102336968B1 (es) |
CN (1) | CN107003322B (es) |
AU (1) | AU2015373584B2 (es) |
BR (1) | BR112017008212B1 (es) |
CA (1) | CA2972306C (es) |
CL (1) | CL2017001071A1 (es) |
CO (1) | CO2017004543A2 (es) |
CR (1) | CR20170297A (es) |
CY (1) | CY1124223T1 (es) |
DK (1) | DK3241026T3 (es) |
EA (1) | EA036328B1 (es) |
ES (1) | ES2871035T3 (es) |
GB (1) | GB201423361D0 (es) |
HR (1) | HRP20210811T1 (es) |
HU (1) | HUE054455T2 (es) |
IL (1) | IL250982B (es) |
LT (1) | LT3241026T (es) |
MA (2) | MA41287B1 (es) |
MD (1) | MD3241026T2 (es) |
MX (1) | MX2017008722A (es) |
MY (1) | MY190199A (es) |
PE (1) | PE20171136A1 (es) |
PH (1) | PH12017500483A1 (es) |
PL (1) | PL3241026T3 (es) |
PT (1) | PT3241026T (es) |
RS (1) | RS61914B1 (es) |
SG (2) | SG10201913988XA (es) |
SI (1) | SI3241026T1 (es) |
TW (1) | TWI632370B (es) |
UA (1) | UA122774C2 (es) |
WO (1) | WO2016107740A1 (es) |
ZA (1) | ZA201701646B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
TWI755158B (zh) * | 2015-03-17 | 2022-02-11 | 德商英麥提克生物技術股份有限公司 | 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合 |
GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
PE20200614A1 (es) | 2017-07-14 | 2020-03-11 | Immatics Biotechnologies Gmbh | Molecula de polipeptido con especificidad dual mejorada |
DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
AU2019218093A1 (en) * | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
KR20200027858A (ko) | 2018-09-05 | 2020-03-13 | 에스케이하이닉스 주식회사 | 메모리 컨트롤러 및 이를 포함하는 메모리 시스템 |
TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
EA202193139A1 (ru) | 2019-05-27 | 2022-03-01 | Имматикс Юс, Инк. | Вирусные векторы и их применение в адоптивной клеточной терапии |
JP2022535421A (ja) | 2019-06-06 | 2022-08-08 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 配列類似ペプチドを使用した対抗選択による選別 |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
KR20220064958A (ko) | 2019-08-09 | 2022-05-19 | 이매틱스 유에스 인코포레이티드 | 펩티드 질량 분광 단편화 예측 방법 |
US20210048442A1 (en) | 2019-08-13 | 2021-02-18 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:mhc binding polypeptides |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
JP2024516699A (ja) | 2021-05-05 | 2024-04-16 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Bma031抗原結合ポリペプチド |
MX2023012902A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Proteinas de union a antigenos que se unen especificamente a prame. |
EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
US20230057987A1 (en) | 2021-07-27 | 2023-02-23 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding ct45 |
WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
US20230190807A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Tcr compounds, compositions, and methods of treating |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003025576A2 (en) | 2001-09-14 | 2003-03-27 | Xzillion Gmbh & Co. Kg | Mass labels |
US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
US6644103B1 (en) | 2002-10-24 | 2003-11-11 | Simmonds Precision Products, Inc. | Method and apparatus for detecting a dry/wet state of a thermistor bead |
AU2003277610A1 (en) | 2002-11-08 | 2004-06-07 | Shuichi Hanada | Method of examining cancer cells and reagent therefor |
EP1714157A2 (en) | 2004-01-28 | 2006-10-25 | Immatics Biotechnologies GmbH | Method for identifying and quantifying of tumour-associated peptides |
JP2008043332A (ja) * | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
RS53782B1 (en) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS |
GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
EP2697655A2 (en) | 2011-04-15 | 2014-02-19 | Micromass UK Limited | Method and apparatus for the analysis of biological samples |
WO2012178030A2 (en) | 2011-06-24 | 2012-12-27 | Applied Isotope Technologies, Inc. | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening |
US10077171B2 (en) * | 2012-10-17 | 2018-09-18 | Grant C. Chustz | Safety barrier for vehicles and cranes |
GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
IL308007A (en) * | 2017-11-06 | 2023-12-01 | Immatics Biotechnologies Gmbh | Transgenic T-cell receptors and immunotherapy using them |
-
2014
- 2014-12-30 GB GBGB1423361.3A patent/GB201423361D0/en not_active Ceased
-
2015
- 2015-12-15 TW TW104142137A patent/TWI632370B/zh active
- 2015-12-15 KR KR1020177017911A patent/KR102336968B1/ko active IP Right Grant
- 2015-12-15 WO PCT/EP2015/079873 patent/WO2016107740A1/en active Application Filing
- 2015-12-15 US US14/969,423 patent/US10545154B2/en active Active
- 2015-12-15 ES ES15822924T patent/ES2871035T3/es active Active
- 2015-12-15 MD MDE20170252T patent/MD3241026T2/ro unknown
- 2015-12-15 BR BR112017008212-8A patent/BR112017008212B1/pt active IP Right Grant
- 2015-12-15 PE PE2017000941A patent/PE20171136A1/es unknown
- 2015-12-15 SG SG10201913988XA patent/SG10201913988XA/en unknown
- 2015-12-15 AU AU2015373584A patent/AU2015373584B2/en active Active
- 2015-12-15 MA MA41287A patent/MA41287B1/fr unknown
- 2015-12-15 UA UAA201701977A patent/UA122774C2/uk unknown
- 2015-12-15 MY MYPI2017700825A patent/MY190199A/en unknown
- 2015-12-15 LT LTEP15822924.5T patent/LT3241026T/lt unknown
- 2015-12-15 JP JP2017521534A patent/JP6735741B2/ja active Active
- 2015-12-15 MX MX2017008722A patent/MX2017008722A/es unknown
- 2015-12-15 CR CR20170297A patent/CR20170297A/es unknown
- 2015-12-15 CA CA2972306A patent/CA2972306C/en active Active
- 2015-12-15 SG SG11201703841VA patent/SG11201703841VA/en unknown
- 2015-12-15 RS RS20210672A patent/RS61914B1/sr unknown
- 2015-12-15 PL PL15822924T patent/PL3241026T3/pl unknown
- 2015-12-15 CN CN201580063711.6A patent/CN107003322B/zh active Active
- 2015-12-15 SI SI201531612T patent/SI3241026T1/sl unknown
- 2015-12-15 DK DK15822924.5T patent/DK3241026T3/da active
- 2015-12-15 EA EA201791148A patent/EA036328B1/ru unknown
- 2015-12-15 EP EP15822924.5A patent/EP3241026B1/en active Active
- 2015-12-15 MA MA40137A patent/MA40137B1/fr unknown
- 2015-12-15 PT PT158229245T patent/PT3241026T/pt unknown
- 2015-12-15 HU HUE15822924A patent/HUE054455T2/hu unknown
-
2017
- 2017-03-07 IL IL250982A patent/IL250982B/en active IP Right Grant
- 2017-03-07 ZA ZA2017/01646A patent/ZA201701646B/en unknown
- 2017-03-14 PH PH12017500483A patent/PH12017500483A1/en unknown
- 2017-04-28 CL CL2017001071A patent/CL2017001071A1/es unknown
- 2017-05-05 CO CONC2017/0004543A patent/CO2017004543A2/es unknown
-
2019
- 2019-11-15 US US16/685,765 patent/US11988669B2/en active Active
-
2021
- 2021-05-19 HR HRP20210811TT patent/HRP20210811T1/hr unknown
- 2021-06-10 CY CY20211100514T patent/CY1124223T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20171136A1 (es) | Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural | |
MX2017003625A (es) | Reactivos y metodos para identificar, enriquecer y/o expander celulas t especificas de antigeno. | |
BR112019008560A2 (pt) | célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação | |
CR20180162A (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CL2021001506A1 (es) | Anticuerpos que se unen a cd3 | |
MX2020004027A (es) | Anticuerpos especificos cd47/pd-l1. | |
PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
BR112017020054A2 (pt) | anticorpos para icos | |
BR112017017293A2 (pt) | método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina | |
JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
GB2525104A (en) | Massively parallel single cell analysis | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
MX2018002293A (es) | Sistemas y métodos para las llamadas variantes de alta precisión. | |
BR112017008251A2 (pt) | usos de um tecido de um porco transgênico que compreende um gene a(1,3) galactosiltransferase, cmah e ß4galnt2 interrompido e de um produto relacionado com a pele, métodos para preparação de um material de transplante para xenoenxerto, para produção de um composto de interesse e para produzir um reagente de cultura de células, e, reagente de cultura de células | |
IN2014DN07531A (es) | ||
ES2672895T3 (es) | Generación de células T específicas de antígeno | |
CO6710946A2 (es) | Método para activar células t auxiliares | |
BR112016028496A2 (pt) | análise quantitativa de proteínas transgênicas | |
BR112016016737A2 (pt) | Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma | |
NI201600127A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES FORMULACIONES Y USO DE ESTA. | |
AR114001A1 (es) | Anticuerpos que se unen a hla- a2 / wt1 | |
PH12016502024A1 (en) | Tonoplast proton/sugar antiporter proteins and the use thereof to increase the saccharose concentration in a saccharose storage organ of plants | |
CO2020005371A2 (es) | Anticuerpos anti-apoc3 y métodos de uso de estos | |
BR112018008296A2 (pt) | método para isolar dna livre de células de uma amostra biológica líquida de um mamífero |